Zobrazeno 1 - 10
of 64
pro vyhledávání: '"Emilia D'Elia"'
Autor:
Luca Fazzini, Arianna Ghirardi, Raul Limonta, Alice Calabrese, Emilia D'Elia, Paolo Canova, Alessandra Fontana, Aurelia Grosu, Attilio Iacovoni, Paola Ferrari, Renata De Maria, Antonello Gavazzi, Roberta Montisci, Michele Senni, Mauro Gori
Publikováno v:
ESC Heart Failure, Vol 11, Iss 5, Pp 3350-3359 (2024)
Abstract Aims The identification of subjects at higher risk for incident heart failure (HF) with preserved ejection fraction (EF) suitable for more intensive preventive programmes remains challenging. We applied phenomapping to the DAVID‐Berg popul
Externí odkaz:
https://doaj.org/article/d0f75b28c55f4a42bf7c0ee6e3847ae0
Autor:
Giulio Balestrieri, Raul Limonta, Enrico Ponti, Anna Merlo, Edoardo Sciatti, Salvatore D’Isa, Mauro Gori, Gavino Casu, Cristina Giannattasio, Michele Senni, Emilia D’Elia
Publikováno v:
Cardiac Failure Review, Vol 10, Iss , Pp - (2024)
Heart failure with preserved ejection fraction (HFpEF) is a clinical syndrome characterised by the presence of diastolic dysfunction and elevated left ventricular filling pressure, in the setting of a left ventricular ejection fraction of at least 50
Externí odkaz:
https://doaj.org/article/241a376307484ebe87b1d808514d07c0
Autor:
Cosimo A. Stamerra, Emilia D'Elia, Mauro Gori, Federica Roncali, Alberto Cereda, Antonello Gavazzi, Claudio Ferri, Michele Senni
Publikováno v:
Frontiers in Cardiovascular Medicine, Vol 10 (2023)
BackgroundHeart failure with preserved ejection fraction (HFpEF) is very frequently associated to sleep breathing disorders (SDB). Red blood cell distribution width (RDW) has been shown to be a potential inflammatory index linked to the degree of hyp
Externí odkaz:
https://doaj.org/article/bf5e2d1a8b8345f4926f8b6c1607ba0f
Publikováno v:
Cardiology Plus, Vol 7, Iss 1, Pp 20-28 (2022)
Abstract. Heart failure with reduced ejection fraction (HFrEF) is a common disease requiring multi-drug therapy. Moreover, it is associated with a poor prognosis, with increasing prevalence in the community. In the last decade, two major drug classes
Externí odkaz:
https://doaj.org/article/cbc95f47feac4fddad4f56982626bb56
Publikováno v:
Cardiac Failure Review, Vol 8, Iss , Pp - (2022)
Heart failure (HF) with preserved left ventricular ejection fraction is a common disease with a poor prognosis and rising prevalence in the community. The current paradigm of treatment includes symptomatic therapy, such as diuretics, and risk factor
Externí odkaz:
https://doaj.org/article/3733938e4b7b43128f22d973d83e4c4b
Autor:
Emilia D’Elia, Mauro Gori, Aurelia Grosu, Annamaria Iorio, Ferdinando Luca Lorini, Anna Falanga, Fabiano Di Marco, Michele Senni
Publikováno v:
BMC Pulmonary Medicine, Vol 21, Iss 1, Pp 1-4 (2021)
Abstract Background Coronavirus Disease 2019 (COVID-19) is a pandemic affecting all countries in the world. Italy has been particularly afflicted by the health emergency, and since the peak phase has passed, major concern regarding medium to long ter
Externí odkaz:
https://doaj.org/article/4570569c605d4749b45aa0d760e05b55
Publikováno v:
Cardiology Plus, Vol 6, Iss 1, Pp 23-29 (2021)
Sacubitril/valsartan (S/V) is a new drug which has been recently recommended by the international guidelines for the treatment of patients with chronic heart failure (HF) with reduced ejection fraction (HFrEF). Compared to angiotensin-converting enzy
Externí odkaz:
https://doaj.org/article/56560761138c4de6b4ce1b8308b3405b
Autor:
Attilio Iacovoni, Emilia D’Elia, Mauro Gori, Fabrizio Oliva, Ferdinando Luca Lorini, Michele Senni
Publikováno v:
Cardiac Failure Review, Vol 5, Iss 2, Pp 78-82 (2019)
Heart failure (HF) is a pandemic syndrome characterised by raised morbidity and mortality. An acute HF event requiring hospitalisation is associated with a poor prognosis, in both the short and the long term. Moreover, early rehospitalisation after d
Externí odkaz:
https://doaj.org/article/922c0a42253145a1bb7f7d37e5f6390a
Publikováno v:
Cardiac Failure Review, Vol 7, Iss , Pp - (2021)
Sacubitril with valsartan (sacubitril/valsartan) is a relatively novel compound that has become a milestone in the treatment of patients with chronic heart failure (HF) with reduced ejection fraction (HFrEF) in the last decade. Contemporary data sugg
Externí odkaz:
https://doaj.org/article/f312d9e2247a4d8ab1a5ab02466600bc
Autor:
Francesca Polverino, Debra A. Stern, Gaetano Ruocco, Elisabetta Balestro, Matteo Bassetti, Marcello Candelli, Bruno Cirillo, Marco Contoli, Angelo Corsico, Filippo D'Amico, Emilia D'Elia, Giuseppe Falco, Stefano Gasparini, Stefano Guerra, Sergio Harari, Monica Kraft, Luigi Mennella, Alberto Papi, Roberto Parrella, Paolo Pelosi, Venerino Poletti, Mario Polverino, Claudio Tana, Roberta Terribile, Jason C. Woods, Fabiano Di Marco, Fernando D. Martinez
Publikováno v:
Frontiers in Cardiovascular Medicine, Vol 7 (2020)
Background: Italy has one of the world's oldest populations, and suffered one the highest death tolls from Coronavirus disease 2019 (COVID-19) worldwide. Older people with cardiovascular diseases (CVDs), and in particular hypertension, are at higher
Externí odkaz:
https://doaj.org/article/2b2ebb86df0241cd97fda85a300025f4